Expleo Solutions Limited
Expleo Solutions Limited (EXPLEOSOL.BO) Stock Competitors & Peer Comparison
See (EXPLEOSOL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Information Technology Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXPLEOSOL.BO | ₹823.55 | -0.25% | 12.7B | 11.90 | ₹68.51 | N/A |
| TCS.NS | ₹2,435.40 | +0.17% | 8.8T | 17.84 | ₹136.06 | +4.49% |
| TCS.BO | ₹2,435.35 | +0.19% | 8.8T | 17.84 | ₹136.04 | +4.49% |
| INFY.NS | ₹1,167.20 | -0.10% | 4.8T | 15.55 | ₹75.75 | +3.82% |
| INFY.BO | ₹1,167.30 | -0.09% | 4.8T | 16.89 | ₹69.73 | +3.82% |
| HCLTECH.BO | ₹1,188.90 | -0.96% | 3.2T | 19.56 | ₹61.39 | +5.00% |
| HCLTECH.NS | ₹1,189.10 | -0.95% | 3.2T | 19.55 | ₹61.39 | +5.00% |
| WIPRO.BO | ₹199.10 | -0.85% | 2.1T | 15.91 | ₹12.56 | +5.51% |
| WIPRO.NS | ₹199.12 | -0.81% | 2.1T | 15.91 | ₹12.56 | +5.51% |
| LTIM.NS | ₹4,535.00 | +2.08% | 1.3T | 28.28 | ₹160.34 | +1.48% |
Stock Comparison
EXPLEOSOL.BO vs TCS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TCS.NS has a market cap of 8.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TCS.NS trades at ₹2,435.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TCS.NS's P/E ratio is 17.84. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TCS.NS's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TCS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.NS's competition here
EXPLEOSOL.BO vs TCS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TCS.BO has a market cap of 8.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TCS.BO trades at ₹2,435.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TCS.BO's P/E ratio is 17.84. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TCS.BO's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TCS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.BO's competition here
EXPLEOSOL.BO vs INFY.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, INFY.NS has a market cap of 4.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while INFY.NS trades at ₹1,167.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas INFY.NS's P/E ratio is 15.55. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to INFY.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to INFY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.NS's competition here
EXPLEOSOL.BO vs INFY.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, INFY.BO has a market cap of 4.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while INFY.BO trades at ₹1,167.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas INFY.BO's P/E ratio is 16.89. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to INFY.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to INFY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.BO's competition here
EXPLEOSOL.BO vs HCLTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HCLTECH.BO has a market cap of 3.2T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while HCLTECH.BO trades at ₹1,188.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas HCLTECH.BO's P/E ratio is 19.56. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to HCLTECH.BO's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.BO's competition here
EXPLEOSOL.BO vs HCLTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HCLTECH.NS has a market cap of 3.2T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while HCLTECH.NS trades at ₹1,189.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas HCLTECH.NS's P/E ratio is 19.55. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to HCLTECH.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.NS's competition here
EXPLEOSOL.BO vs WIPRO.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, WIPRO.BO has a market cap of 2.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while WIPRO.BO trades at ₹199.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas WIPRO.BO's P/E ratio is 15.91. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to WIPRO.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to WIPRO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.BO's competition here
EXPLEOSOL.BO vs WIPRO.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, WIPRO.NS has a market cap of 2.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while WIPRO.NS trades at ₹199.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas WIPRO.NS's P/E ratio is 15.91. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to WIPRO.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to WIPRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.NS's competition here
EXPLEOSOL.BO vs LTIM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTIM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while LTIM.NS trades at ₹4,535.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas LTIM.NS's P/E ratio is 28.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to LTIM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTIM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.NS's competition here
EXPLEOSOL.BO vs TECHM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TECHM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TECHM.NS trades at ₹1,466.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TECHM.NS's P/E ratio is 26.78. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TECHM.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TECHM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.NS's competition here
EXPLEOSOL.BO vs TECHM.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TECHM.BO has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TECHM.BO trades at ₹1,466.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TECHM.BO's P/E ratio is 27.84. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TECHM.BO's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TECHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.BO's competition here
EXPLEOSOL.BO vs LTIM.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTIM.BO has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while LTIM.BO trades at ₹4,314.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas LTIM.BO's P/E ratio is 26.83. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to LTIM.BO's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTIM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.BO's competition here
EXPLEOSOL.BO vs LTM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while LTM.NS trades at ₹4,318.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas LTM.NS's P/E ratio is 25.42. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to LTM.NS's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTM.NS's competition here
EXPLEOSOL.BO vs PERSISTENT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PERSISTENT.BO has a market cap of 753.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while PERSISTENT.BO trades at ₹5,015.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas PERSISTENT.BO's P/E ratio is 43.50. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to PERSISTENT.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PERSISTENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.BO's competition here
EXPLEOSOL.BO vs PERSISTENT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PERSISTENT.NS has a market cap of 752.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while PERSISTENT.NS trades at ₹5,014.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas PERSISTENT.NS's P/E ratio is 40.46. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to PERSISTENT.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PERSISTENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.NS's competition here
EXPLEOSOL.BO vs MPHASIS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MPHASIS.BO has a market cap of 421.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MPHASIS.BO trades at ₹2,221.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MPHASIS.BO's P/E ratio is 23.44. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MPHASIS.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MPHASIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.BO's competition here
EXPLEOSOL.BO vs MPHASIS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MPHASIS.NS has a market cap of 421.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MPHASIS.NS trades at ₹2,218.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MPHASIS.NS's P/E ratio is 23.44. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MPHASIS.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MPHASIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.NS's competition here
EXPLEOSOL.BO vs LTTS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTTS.BO has a market cap of 396.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while LTTS.BO trades at ₹3,799.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas LTTS.BO's P/E ratio is 32.37. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to LTTS.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.BO's competition here
EXPLEOSOL.BO vs LTTS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, LTTS.NS has a market cap of 396.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while LTTS.NS trades at ₹3,804.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas LTTS.NS's P/E ratio is 32.33. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to LTTS.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTTS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.NS's competition here
EXPLEOSOL.BO vs COFORGE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, COFORGE.NS has a market cap of 392.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while COFORGE.NS trades at ₹1,280.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas COFORGE.NS's P/E ratio is 34.88. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to COFORGE.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to COFORGE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.NS's competition here
EXPLEOSOL.BO vs COFORGE.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, COFORGE.BO has a market cap of 392.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while COFORGE.BO trades at ₹1,280.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas COFORGE.BO's P/E ratio is 34.97. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to COFORGE.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to COFORGE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.BO's competition here
EXPLEOSOL.BO vs HEXT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HEXT.NS has a market cap of 275.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while HEXT.NS trades at ₹459.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas HEXT.NS's P/E ratio is 20.39. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to HEXT.NS's ROE of +0.24%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to HEXT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXT.NS's competition here
EXPLEOSOL.BO vs TATATECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TATATECH.NS has a market cap of 253.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TATATECH.NS trades at ₹627.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TATATECH.NS's P/E ratio is 47.78. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TATATECH.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TATATECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.NS's competition here
EXPLEOSOL.BO vs TATATECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TATATECH.BO has a market cap of 253B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TATATECH.BO trades at ₹627.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TATATECH.BO's P/E ratio is 47.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TATATECH.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TATATECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.BO's competition here
EXPLEOSOL.BO vs KPITTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, KPITTECH.NS has a market cap of 210.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while KPITTECH.NS trades at ₹748.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas KPITTECH.NS's P/E ratio is 29.39. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to KPITTECH.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to KPITTECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check KPITTECH.NS's competition here
EXPLEOSOL.BO vs KPITTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, KPITTECH.BO has a market cap of 210.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while KPITTECH.BO trades at ₹748.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas KPITTECH.BO's P/E ratio is 29.38. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to KPITTECH.BO's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to KPITTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check KPITTECH.BO's competition here
EXPLEOSOL.BO vs REDINGTON.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, REDINGTON.BO has a market cap of 170.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while REDINGTON.BO trades at ₹223.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas REDINGTON.BO's P/E ratio is 9.68. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to REDINGTON.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to REDINGTON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.BO's competition here
EXPLEOSOL.BO vs REDINGTON.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, REDINGTON.NS has a market cap of 170.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while REDINGTON.NS trades at ₹223.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas REDINGTON.NS's P/E ratio is 9.68. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to REDINGTON.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to REDINGTON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.NS's competition here
EXPLEOSOL.BO vs FSL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, FSL.BO has a market cap of 150.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while FSL.BO trades at ₹243.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas FSL.BO's P/E ratio is 24.51. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to FSL.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to FSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.BO's competition here
EXPLEOSOL.BO vs FSL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, FSL.NS has a market cap of 150.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while FSL.NS trades at ₹243.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas FSL.NS's P/E ratio is 24.51. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to FSL.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to FSL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.NS's competition here
EXPLEOSOL.BO vs HEXAWARE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HEXAWARE.NS has a market cap of 141.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while HEXAWARE.NS trades at ₹470.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas HEXAWARE.NS's P/E ratio is 22.98. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to HEXAWARE.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HEXAWARE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXAWARE.NS's competition here
EXPLEOSOL.BO vs ECLERX.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ECLERX.BO has a market cap of 136.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ECLERX.BO trades at ₹1,584.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ECLERX.BO's P/E ratio is 20.79. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ECLERX.BO's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ECLERX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ECLERX.BO's competition here
EXPLEOSOL.BO vs ECLERX.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ECLERX.NS has a market cap of 135B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ECLERX.NS trades at ₹1,581.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ECLERX.NS's P/E ratio is 20.83. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ECLERX.NS's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ECLERX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ECLERX.NS's competition here
EXPLEOSOL.BO vs ZENSARTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ZENSARTECH.BO has a market cap of 116.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ZENSARTECH.BO trades at ₹524.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ZENSARTECH.BO's P/E ratio is 15.93. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ZENSARTECH.BO's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.BO's competition here
EXPLEOSOL.BO vs ZENSARTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ZENSARTECH.NS has a market cap of 116.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ZENSARTECH.NS trades at ₹525.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ZENSARTECH.NS's P/E ratio is 15.34. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ZENSARTECH.NS's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.NS's competition here
EXPLEOSOL.BO vs BSOFT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, BSOFT.NS has a market cap of 103.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while BSOFT.NS trades at ₹372.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas BSOFT.NS's P/E ratio is 22.21. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to BSOFT.NS's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to BSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.NS's competition here
EXPLEOSOL.BO vs BSOFT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, BSOFT.BO has a market cap of 103.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while BSOFT.BO trades at ₹372.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas BSOFT.BO's P/E ratio is 22.25. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to BSOFT.BO's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to BSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.BO's competition here
EXPLEOSOL.BO vs SONATSOFTW.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SONATSOFTW.BO has a market cap of 72.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SONATSOFTW.BO trades at ₹269.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SONATSOFTW.BO's P/E ratio is 16.02. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SONATSOFTW.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SONATSOFTW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.BO's competition here
EXPLEOSOL.BO vs SONATSOFTW.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SONATSOFTW.NS has a market cap of 72.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SONATSOFTW.NS trades at ₹269.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SONATSOFTW.NS's P/E ratio is 16.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SONATSOFTW.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SONATSOFTW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.NS's competition here
EXPLEOSOL.BO vs RSYSTEMINT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RSYSTEMINT.BO has a market cap of 63.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while RSYSTEMINT.BO trades at ₹531.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas RSYSTEMINT.BO's P/E ratio is 106.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to RSYSTEMINT.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMINT.BO's competition here
EXPLEOSOL.BO vs HAPPSTMNDS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HAPPSTMNDS.NS has a market cap of 56.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while HAPPSTMNDS.NS trades at ₹387.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas HAPPSTMNDS.NS's P/E ratio is 30.57. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to HAPPSTMNDS.NS's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to HAPPSTMNDS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.NS's competition here
EXPLEOSOL.BO vs HAPPSTMNDS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, HAPPSTMNDS.BO has a market cap of 56.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while HAPPSTMNDS.BO trades at ₹387.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas HAPPSTMNDS.BO's P/E ratio is 30.57. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to HAPPSTMNDS.BO's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to HAPPSTMNDS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.BO's competition here
EXPLEOSOL.BO vs MASTEK.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MASTEK.NS has a market cap of 51.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MASTEK.NS trades at ₹1,692.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MASTEK.NS's P/E ratio is 12.82. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MASTEK.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MASTEK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.NS's competition here
EXPLEOSOL.BO vs MASTEK.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MASTEK.BO has a market cap of 51.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MASTEK.BO trades at ₹1,695.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MASTEK.BO's P/E ratio is 12.80. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MASTEK.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MASTEK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.BO's competition here
EXPLEOSOL.BO vs DATAMATICS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DATAMATICS.BO has a market cap of 43.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while DATAMATICS.BO trades at ₹778.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas DATAMATICS.BO's P/E ratio is 22.36. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to DATAMATICS.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DATAMATICS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.BO's competition here
EXPLEOSOL.BO vs DATAMATICS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DATAMATICS.NS has a market cap of 43.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while DATAMATICS.NS trades at ₹779.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas DATAMATICS.NS's P/E ratio is 22.32. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to DATAMATICS.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DATAMATICS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.NS's competition here
EXPLEOSOL.BO vs CAMS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CAMS.NS has a market cap of 39.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while CAMS.NS trades at ₹815.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas CAMS.NS's P/E ratio is 41.64. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to CAMS.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CAMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.NS's competition here
EXPLEOSOL.BO vs CAMS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CAMS.BO has a market cap of 39.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while CAMS.BO trades at ₹816.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas CAMS.BO's P/E ratio is 41.62. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to CAMS.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CAMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.BO's competition here
EXPLEOSOL.BO vs ASMTEC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ASMTEC.BO has a market cap of 37.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ASMTEC.BO trades at ₹3,305.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ASMTEC.BO's P/E ratio is 77.95. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ASMTEC.BO's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ASMTEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ASMTEC.BO's competition here
EXPLEOSOL.BO vs CIGNITITEC.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CIGNITITEC.NS has a market cap of 32B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while CIGNITITEC.NS trades at ₹1,274.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas CIGNITITEC.NS's P/E ratio is 10.62. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to CIGNITITEC.NS's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CIGNITITEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.NS's competition here
EXPLEOSOL.BO vs CIGNITITEC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CIGNITITEC.BO has a market cap of 31.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while CIGNITITEC.BO trades at ₹1,274.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas CIGNITITEC.BO's P/E ratio is 10.57. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to CIGNITITEC.BO's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CIGNITITEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.BO's competition here
EXPLEOSOL.BO vs RSYSTEMS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RSYSTEMS.BO has a market cap of 31.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while RSYSTEMS.BO trades at ₹288.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas RSYSTEMS.BO's P/E ratio is 17.94. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to RSYSTEMS.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.BO's competition here
EXPLEOSOL.BO vs RSYSTEMS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RSYSTEMS.NS has a market cap of 31.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while RSYSTEMS.NS trades at ₹288.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas RSYSTEMS.NS's P/E ratio is 17.80. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to RSYSTEMS.NS's ROE of +0.24%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.NS's competition here
EXPLEOSOL.BO vs RPSGVENT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RPSGVENT.NS has a market cap of 29.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while RPSGVENT.NS trades at ₹895.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas RPSGVENT.NS's P/E ratio is -31.64. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to RPSGVENT.NS's ROE of -0.03%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RPSGVENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.NS's competition here
EXPLEOSOL.BO vs RPSGVENT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, RPSGVENT.BO has a market cap of 29.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while RPSGVENT.BO trades at ₹896.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas RPSGVENT.BO's P/E ratio is -31.63. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to RPSGVENT.BO's ROE of -0.03%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RPSGVENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.BO's competition here
EXPLEOSOL.BO vs PROTEAN.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PROTEAN.NS has a market cap of 21.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while PROTEAN.NS trades at ₹567.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas PROTEAN.NS's P/E ratio is 23.59. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to PROTEAN.NS's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PROTEAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.NS's competition here
EXPLEOSOL.BO vs PROTEAN.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, PROTEAN.BO has a market cap of 21.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while PROTEAN.BO trades at ₹567.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas PROTEAN.BO's P/E ratio is 23.57. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to PROTEAN.BO's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PROTEAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.BO's competition here
EXPLEOSOL.BO vs SASKEN.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SASKEN.NS has a market cap of 20.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SASKEN.NS trades at ₹1,338.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SASKEN.NS's P/E ratio is 53.27. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SASKEN.NS's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SASKEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.NS's competition here
EXPLEOSOL.BO vs SASKEN.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SASKEN.BO has a market cap of 20.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SASKEN.BO trades at ₹1,338.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SASKEN.BO's P/E ratio is 53.11. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SASKEN.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SASKEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.BO's competition here
EXPLEOSOL.BO vs SAKSOFT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SAKSOFT.BO has a market cap of 17.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SAKSOFT.BO trades at ₹147.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SAKSOFT.BO's P/E ratio is 14.46. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SAKSOFT.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SAKSOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.BO's competition here
EXPLEOSOL.BO vs SAKSOFT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SAKSOFT.NS has a market cap of 17.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SAKSOFT.NS trades at ₹148.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SAKSOFT.NS's P/E ratio is 14.45. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SAKSOFT.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SAKSOFT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.NS's competition here
EXPLEOSOL.BO vs ACCELYA.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ACCELYA.NS has a market cap of 17.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ACCELYA.NS trades at ₹1,160.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ACCELYA.NS's P/E ratio is 15.95. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ACCELYA.NS's ROE of +0.39%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ACCELYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.NS's competition here
EXPLEOSOL.BO vs ACCELYA.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ACCELYA.BO has a market cap of 17.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ACCELYA.BO trades at ₹1,159.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ACCELYA.BO's P/E ratio is 15.95. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ACCELYA.BO's ROE of +0.39%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ACCELYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.BO's competition here
EXPLEOSOL.BO vs MCLOUD.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MCLOUD.BO has a market cap of 16.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MCLOUD.BO trades at ₹27.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MCLOUD.BO's P/E ratio is 14.97. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MCLOUD.BO's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MCLOUD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.BO's competition here
EXPLEOSOL.BO vs MCLOUD.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MCLOUD.NS has a market cap of 16B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MCLOUD.NS trades at ₹27.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MCLOUD.NS's P/E ratio is 14.96. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MCLOUD.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MCLOUD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.NS's competition here
EXPLEOSOL.BO vs DSSL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DSSL.BO has a market cap of 15.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while DSSL.BO trades at ₹1,363.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas DSSL.BO's P/E ratio is 18.93. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to DSSL.BO's ROE of +0.36%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DSSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.BO's competition here
EXPLEOSOL.BO vs DSSL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DSSL.NS has a market cap of 15.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while DSSL.NS trades at ₹1,362.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas DSSL.NS's P/E ratio is 18.93. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to DSSL.NS's ROE of +0.36%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DSSL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.NS's competition here
EXPLEOSOL.BO vs MMWL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MMWL.BO has a market cap of 14.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MMWL.BO trades at ₹14.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MMWL.BO's P/E ratio is 248.80. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MMWL.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MMWL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MMWL.BO's competition here
EXPLEOSOL.BO vs AURUM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, AURUM.NS has a market cap of 13.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while AURUM.NS trades at ₹180.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas AURUM.NS's P/E ratio is 700.31. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to AURUM.NS's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to AURUM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.NS's competition here
EXPLEOSOL.BO vs AURUM.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, AURUM.BO has a market cap of 13.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while AURUM.BO trades at ₹181.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas AURUM.BO's P/E ratio is 726.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to AURUM.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to AURUM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.BO's competition here
EXPLEOSOL.BO vs EXPLEOSOL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, EXPLEOSOL.NS has a market cap of 12.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while EXPLEOSOL.NS trades at ₹824.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas EXPLEOSOL.NS's P/E ratio is 11.96. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to EXPLEOSOL.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to EXPLEOSOL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check EXPLEOSOL.NS's competition here
EXPLEOSOL.BO vs ORIENTTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ORIENTTECH.NS has a market cap of 12.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ORIENTTECH.NS trades at ₹284.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ORIENTTECH.NS's P/E ratio is 58.60. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ORIENTTECH.NS's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ORIENTTECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ORIENTTECH.NS's competition here
EXPLEOSOL.BO vs BGDL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, BGDL.BO has a market cap of 11.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while BGDL.BO trades at ₹117.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas BGDL.BO's P/E ratio is 411.79. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to BGDL.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to BGDL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BGDL.BO's competition here
EXPLEOSOL.BO vs NINSYS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, NINSYS.BO has a market cap of 10B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while NINSYS.BO trades at ₹519.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas NINSYS.BO's P/E ratio is 32.50. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to NINSYS.BO's ROE of +0.49%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to NINSYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.BO's competition here
EXPLEOSOL.BO vs NINSYS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, NINSYS.NS has a market cap of 9.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while NINSYS.NS trades at ₹519.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas NINSYS.NS's P/E ratio is 32.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to NINSYS.NS's ROE of +0.44%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to NINSYS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.NS's competition here
EXPLEOSOL.BO vs 3IINFOTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, 3IINFOTECH.BO has a market cap of 9.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while 3IINFOTECH.BO trades at ₹54.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas 3IINFOTECH.BO's P/E ratio is 111.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to 3IINFOTECH.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to 3IINFOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check 3IINFOTECH.BO's competition here
EXPLEOSOL.BO vs ADSL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ADSL.BO has a market cap of 7.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ADSL.BO trades at ₹132.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ADSL.BO's P/E ratio is 23.69. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ADSL.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ADSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.BO's competition here
EXPLEOSOL.BO vs ADSL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ADSL.NS has a market cap of 7.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ADSL.NS trades at ₹132.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ADSL.NS's P/E ratio is 23.69. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ADSL.NS's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ADSL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.NS's competition here
EXPLEOSOL.BO vs XCHANGING.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, XCHANGING.NS has a market cap of 7.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while XCHANGING.NS trades at ₹69.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas XCHANGING.NS's P/E ratio is 13.04. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to XCHANGING.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to XCHANGING.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.NS's competition here
EXPLEOSOL.BO vs XCHANGING.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, XCHANGING.BO has a market cap of 7.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while XCHANGING.BO trades at ₹69.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas XCHANGING.BO's P/E ratio is 12.96. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to XCHANGING.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to XCHANGING.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.BO's competition here
EXPLEOSOL.BO vs VAKRANGEE.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, VAKRANGEE.BO has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while VAKRANGEE.BO trades at ₹6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas VAKRANGEE.BO's P/E ratio is 60.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to VAKRANGEE.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to VAKRANGEE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.BO's competition here
EXPLEOSOL.BO vs VAKRANGEE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, VAKRANGEE.NS has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while VAKRANGEE.NS trades at ₹6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas VAKRANGEE.NS's P/E ratio is 59.91. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to VAKRANGEE.NS's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to VAKRANGEE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.NS's competition here
EXPLEOSOL.BO vs MINDTECK.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MINDTECK.NS has a market cap of 6.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MINDTECK.NS trades at ₹213.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MINDTECK.NS's P/E ratio is 24.30. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MINDTECK.NS's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MINDTECK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.NS's competition here
EXPLEOSOL.BO vs MINDTECK.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, MINDTECK.BO has a market cap of 6.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while MINDTECK.BO trades at ₹214.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas MINDTECK.BO's P/E ratio is 24.26. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to MINDTECK.BO's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MINDTECK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.BO's competition here
EXPLEOSOL.BO vs ONWARDTEC.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ONWARDTEC.NS has a market cap of 5.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ONWARDTEC.NS trades at ₹244.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ONWARDTEC.NS's P/E ratio is 12.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ONWARDTEC.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ONWARDTEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.NS's competition here
EXPLEOSOL.BO vs ONWARDTEC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, ONWARDTEC.BO has a market cap of 5.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while ONWARDTEC.BO trades at ₹245.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas ONWARDTEC.BO's P/E ratio is 12.22. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to ONWARDTEC.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ONWARDTEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.BO's competition here
EXPLEOSOL.BO vs DIGISPICE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DIGISPICE.NS has a market cap of 4.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while DIGISPICE.NS trades at ₹20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas DIGISPICE.NS's P/E ratio is 77.93. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to DIGISPICE.NS's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DIGISPICE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.NS's competition here
EXPLEOSOL.BO vs DIGISPICE.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, DIGISPICE.BO has a market cap of 4.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while DIGISPICE.BO trades at ₹21.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas DIGISPICE.BO's P/E ratio is 77.78. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to DIGISPICE.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DIGISPICE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.BO's competition here
EXPLEOSOL.BO vs SIGMA.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SIGMA.NS has a market cap of 4.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SIGMA.NS trades at ₹44.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SIGMA.NS's P/E ratio is 17.91. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SIGMA.NS's ROE of +0.51%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SIGMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.NS's competition here
EXPLEOSOL.BO vs SIGMA.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SIGMA.BO has a market cap of 4.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SIGMA.BO trades at ₹43.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SIGMA.BO's P/E ratio is 17.85. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SIGMA.BO's ROE of +0.51%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SIGMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.BO's competition here
EXPLEOSOL.BO vs TERASOFT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TERASOFT.NS has a market cap of 4.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TERASOFT.NS trades at ₹348.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TERASOFT.NS's P/E ratio is 20.71. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TERASOFT.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TERASOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.NS's competition here
EXPLEOSOL.BO vs TERASOFT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, TERASOFT.BO has a market cap of 4.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while TERASOFT.BO trades at ₹346.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas TERASOFT.BO's P/E ratio is 20.60. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to TERASOFT.BO's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TERASOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.BO's competition here
EXPLEOSOL.BO vs XTGLOBAL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, XTGLOBAL.BO has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while XTGLOBAL.BO trades at ₹31.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas XTGLOBAL.BO's P/E ratio is 47.58. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to XTGLOBAL.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to XTGLOBAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XTGLOBAL.BO's competition here
EXPLEOSOL.BO vs SILVERTUC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SILVERTUC.BO has a market cap of 4.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SILVERTUC.BO trades at ₹167.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SILVERTUC.BO's P/E ratio is 64.08. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SILVERTUC.BO's ROE of +0.24%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SILVERTUC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.BO's competition here
EXPLEOSOL.BO vs SILVERTUC.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, SILVERTUC.NS has a market cap of 4.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while SILVERTUC.NS trades at ₹166.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas SILVERTUC.NS's P/E ratio is 63.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to SILVERTUC.NS's ROE of +0.24%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SILVERTUC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.NS's competition here
EXPLEOSOL.BO vs CYBERTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CYBERTECH.BO has a market cap of 4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while CYBERTECH.BO trades at ₹127.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas CYBERTECH.BO's P/E ratio is 12.20. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to CYBERTECH.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CYBERTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.BO's competition here
EXPLEOSOL.BO vs CYBERTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, CYBERTECH.NS has a market cap of 4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while CYBERTECH.NS trades at ₹128.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas CYBERTECH.NS's P/E ratio is 12.12. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to CYBERTECH.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CYBERTECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.NS's competition here
EXPLEOSOL.BO vs 3IINFOLTD.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, 3IINFOLTD.BO has a market cap of 3.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while 3IINFOLTD.BO trades at ₹17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas 3IINFOLTD.BO's P/E ratio is 5.72. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to 3IINFOLTD.BO's ROE of +0.76%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to 3IINFOLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check 3IINFOLTD.BO's competition here
EXPLEOSOL.BO vs INSPIRISYS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 12.7B. In comparison, INSPIRISYS.BO has a market cap of 3.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹823.55, while INSPIRISYS.BO trades at ₹87.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.90, whereas INSPIRISYS.BO's P/E ratio is 9.31. In terms of profitability, EXPLEOSOL.BO's ROE is +0.15%, compared to INSPIRISYS.BO's ROE of +0.82%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to INSPIRISYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INSPIRISYS.BO's competition here